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Abstract: Pasteurella multocida—a gram-negative bacterium with a broad host range and ubiquitous distribution—is
a serious problem in ducks, and the best method of control is vaccination with locally prevalent strains. The present
study was conducted to compare the immunopotency of vaccines employing P. multocida biofilms and capsule
enhanced organisms with ordinary broth grown organisms in 1-month-old ducklings, by measuring the humoral
immune response and the protection conferred by each vaccine during homologous challenge with virulent organisms.
Formalin inactivated oil adjuvant bacterin vaccines were prepared from Pasteurella multocida A: 1. They were grown
in conventional broth, capsule enhancement medium, and under biofilm mode. Four different groups of birds were
vaccinated with the respective vaccines by intramuscular route, and the immunopotency of the vaccines was assessed
by employing passive haemagglutination (PHA) and homologous challenging with virulent organisms. The PHA titres
obtained for the biofilm vaccine group on day 14 postvaccination were much higher than those for the other 2 groups.
They also provided 10% more protection when challenged with 200 and 100 median “lethal dose” doses. The capsule
enhanced vaccine and conventional bacterin revealed similar results.
Key words: Pasteurella multocida A: 1, biofilm vaccine, capsule enhanced vaccine, passive haemagglutination,
homologous challenging

*E-mail: krishnannairg@gmail.com

367

Immunopotency of novel oil adjuvant vaccines employing Pasteurella multocida biofilm and capsule enhanced organisms in ducklings

Introduction

Pathogenicity in mice and lethal dose in ducklings

Among the diseases of ducks, pasteurellosis caused
by Pasteurella multocida (P. multocida) forms a major
bottleneck in the burgeoning poultry industry in
India. Indiscriminate use of once effective antibiotics
has led to drug resistance, making prophylactic
immunisation the exclusive alternative to preclude
the disease.

Five mice 6 to 8 weeks old were inoculated with 0.3
× 108 organisms/0.1 mL of phosphate buffered saline
(PBS, pH 7.4) by intraperitoneal route, keeping
appropriate controls.

In India several commercial vaccines are in vogue
for pasteurellosis, but none of them provide a lasting
and broad immunity. It was found that organisms
grown under conditions mimicking in vivo
conferred better immunity than ordinary laboratory
grown organisms, plausibly due to the expression of
cross protection factors (1). Bacterial biofilms are a
structured community of bacterial cells enshrined
in a protective covering of exopolysaccharide and
are increasingly similar to in vivo growth. They
express many novel proteins that could be the
immunodominant antigens and, if used as vaccine,
may result in a better immune response (2).
Many researchers have insisted on the use of
a virulent form of bacteria for the preparation of
inactivated vaccines (3). Capsule is an important
virulence factor for avian P. multocida (4). Serum was
found to enhance the capsule formation of bacteria
and yeast (5), and such capsule enhanced organisms
will be beneficial for vaccine production.
The present study was conducted to compare
the immunopotency of vaccines employing P.
multocida biofilms and capsule enhanced organisms
with ordinary broth grown organisms in 1-monthold ducklings by measuring the humoral immune
response and the protection conferred by each
vaccine during homologous challenge with virulent
organisms.
Materials and methods
Vaccine strain: The Pasteurella multocida A: 1
strain (DP1) isolated from Niranam Duck Farm
(Pathanamthitta District, Kerala, India); serotyped at
IVRI, Izatnagar; and maintained in the Department
of Veterinary Microbiology, College of Veterinary
and Animal Sciences (COVAS), Mannuthy, was used
for the entire study.
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Median lethal dose (LD50) of DP1 was determined
in 1-month-old ducklings. Briefly, Pasteurella
multocida A: 1 strain was passaged in mice to get a
fully encapsulated virulent form, and the virulent
organisms isolated from mice were made into serial
10 fold dilutions. The 1-month-old ducklings were
randomly assigned to 9 groups of 6 ducklings each.
The first 8 groups were separately inoculated with
the different dilutions of the bacteria, with a dose
of 0.1 mL per bird subcutaneously at the wing web;
the ninth group served as control and was sham
inoculated with 0.1 mL of sterile PBS (pH 7.4).
Mortality was recorded 1 week postinoculation. All
the dead ducklings were examined for specific gross
lesions caused by P. multocida, and reisolation of the
organism on blood agar from heart blood, liver, and
spleen was attempted. The method described by Reed
and Muench (6) was used for LD50 calculation.
Preparation of bacterial suspensions for vaccine
preparation
The freeze-dried stock DP1 was reconstituted with
0.5 mL of Tryptone soya broth (TSB), streaked
onto dextrose starch agar (DSA), and following
an incubation period of 24 h a typical colony was
selected for the preparation of bacterins.
The organisms were grown under the following 3
conditions: (a) 3% TSB for 24 h at 37 °C, conventional
vaccine (CV); (b) 3% TSB supplemented with 10%
foetal bovine serum (FBS) and 0.5% yeast extract for
12 h at 37 °C, capsule enhanced vaccine (CEV); and
(c) TSB (0.32%) supplemented with 0.3% bentonite
clay for 3 days at 42 °C, biofilm vaccine (BV).
Organisms grown in TSB (3%) and under
capsule enhancement conditions were harvested by
centrifugation at 3000 × g for 10 min, washed 3 times
in the PBS (pH 7.4), and were then resuspended in
0.5% formol saline to a concentration of 3 × 109 cells/
mL. The biofilm bacterin was prepared as described
by Vadakel (7). Briefly, the bacteria were cultured in
Tryptone soya broth (0.32%), supplemented with
0.3% bentonite clay powder (Merck, Mumbai), for 3
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days at 42 °C. The attached bacterial mass was then
harvested by low speed centrifugation (600 × g for 10
min), washed several times, and separated from the
bentonite clay by vigorous vortexing.

Sonicated antigen was prepared as described by
Ireland et al. (9), excepting the addition of egg white
lysozyme. Passive haemagglutination was performed
using the method of Sawada et al. (10).

All bacterial cultures thus prepared were allowed
to stand at room temperature for 48 h, with occasional
shaking, so that the formalin could act.

Homologous
challenging
of
birds
postvaccination: From each vaccinated group,
10 birds were subjected to homologous challenge
by intramuscular route with 0.1 mL of inoculum
containing 200 LD50 and 100 LD50 of fully encapsulated
virulent form of P. multocida serotype A: 1 on the 28th
and 42nd day PV, respectively. The challenged birds
were observed for a period of 2 weeks postchallenge
for mortality/clinical signs. All dead birds were
examined for specific lesions of pasteurellosis, and
reisolation of the organism on blood agar from heart
blood, liver, and spleen was attempted.

The sterility of all the bacterins was tested on
blood agar at 37 °C for 72 h under 5% carbon dioxide.
Preparation of vaccines
Oil adjuvanated vaccines were prepared from the
above bacterins, and the stability of vaccines was
assessed (8). The sterility of the prepared vaccines
was tested individually in blood agar and Tryptic
soy agar (TSA), modified thioglycolate medium, and
Sabouraud’s dextrose agar (SDA). The toxicity of the
vaccines was assessed by injecting the exact dose (0.5
mL) and a double dose of vaccine intramuscularly
into 3 ducklings each. The vaccinated birds were
observed for a period of 7 days for any untoward
reactions or clinical manifestations.

Statistical analysis: A one-way analysis of
variance (ANOVA) of the logarithm of IHA titres of
sera collected from the ducks on different days was
done to compare the immunopotency of the vaccines.
The significance of mean differences between vaccine
groups was tested using Bartlett’s test.

Potency testing in ducklings
A total of 160 ducklings 4 weeks old purchased from
a private breeder were divided into 4 groups with 40
birds each. The vaccination schedule was as follows:
Group I: Conventional vaccine (CV)
Group II: Capsule enhanced vaccine (CEV)
Group III: Biofilm vaccine (BV)
Group IV: Control group
The first 3 groups were inoculated intramuscularly
in the thigh region with the respective vaccines (0.5
mL/bird). The control group was sham vaccinated
with PBS (pH 7.4).
Serological assay
Collection of serum from vaccinates: Blood was
collected from all 160 ducks at weekly intervals up
to the 28th day postvaccination (PV) and on day 42
PV by cardiac puncture or by jugular venipuncture;
serum was separated from each blood sample.
Passive haemagglutination (PHA)
Passive haemagglutination was performed using
sheep red blood cell (SRBC) fixed with glutaraldehyde
and sensitised with sonicated antigen of P. multocida.

Results
Pathogenicity and lethal dose testing in mice and
ducklings
Pasteurella multocida serotype A: 1 killed the mice
within 8 h when injected by intraperitoneal route. The
median lethal dose was 10−7.4/0.1 mL subcutaneous
dose (Table 1).
Biofilm formation of DP1
The organism adhered over the inert material,
bentonite clay, under nutrient restricted conditions;
the biofilm formation peaked on day 3, with a mean
plate count of 1.54 × 106 CFU/g of bentonite clay.
Preparation of vaccines
All the prepared vaccines were homogeneous
suspensions, which facilitated intramuscular
administration. The prepared vaccines were sterile
and did not cause any untoward effects except for a
transient lameness in ducks, which subsided after 1
day postinoculation.
Passive haemagglutination (PHA)
Antibodies were detected in the postvaccination sera
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Table 1. LD50 of Pasteurella multocida (DP1) in 1-month-old ducklings.
Organisms present
in 0.1 mL of
inoculum

No. of birds
inoculated

No. dead

10−1

3 × 107

6

6

−2

10

3 × 10

6

6

10−3

3 × 105

6

−4

4

10

3

10−6
−7

Dilution

Accumulative value*

% of dead
birds

Dead

Live

Ratio of dead
birds

0

41

0

41/41

100

6

0

35

0

35/35

100

6

0

29

0

29/29

100

6

6

0

23

0

23/23

100

3 × 10

6

6

0

17

0

17/17

100

3 × 102

6

6

0

11

0

11/11

100

10

3 × 10

1

6

4

2

5

2

5/7

71.4

10−8

3 × 100

6

1

5

1

7

1/8

12.5

3 × 10

10

−5

No. live

*Accumulative values for the total number of animals that died or survived were obtained by adding in the direction of lowest to highest
values. Median lethal dose was calculated from the proportionate distance, as per Reed and Muench (6).

as early as 7 days in the first 3 vaccinated groups, and
the titre increased during subsequent days, although
the pattern differed on different days. The control
group, which was sham vaccinated with PBS, did not
reveal many antibody titres irrespective of the day
of collection. There was no significant difference in
mean titres among the groups during the seventh
day. At day 14 the PV biofilm group was significantly
different from the other 2 vaccine groups and the
control. By days 21 and 28 all the vaccine groups
were similar. At day 42 the biofilm vaccine group
was found to maintain the titres while the titres of
groups I and II decreased, making them significantly
different. All the vaccine groups showed a significant
difference from the control group at all stages of the
study. Groups I and II had no significant difference in
the mean titre during the entire study. Notably, only

the biofilm group was able to maintain its titre up to
the 42nd day. The mean logarithmic PHA titres of
individual sera collected at days 7, 14, 21, 28, and 42
PV are shown in Table 2.
Direct homologous challenge
When challenged with a 200 LD50 dose, more
ducklings were dead in all groups; however, at both
100 and 200 LD50 doses, the biofilm group showed
10% more protection. CV and CEV revealed
similar protection rates (Table 3). The postmortem
examination of dead birds from all vaccine groups
revealed gross lesions that were less severe than those
in the control group. The culture of heart blood and
liver of dead birds onto blood agar revealed typical
colonies of P. multocida even though the lesions were
less severe.

Table 2. Mean logarithmic PHA titres of serum samples of birds, postvaccination.

Days postvaccination

(Mean ± SE)
CV

CEV

BV

7*

0.386 ± 0.13

0.718 ± 0.14

0.631 ± 0.18

0.266 ± 0.1

14

0.84 ± 0.14b

0.77 ± 0.16b

1.397 ± 0.1a

0.250 ± 0.08c

21

0.863 ± 0.06a

0.889 ± 0.06a

1.008 ± 0.08a

0.302 ± 0.05b

28

0.946 ± 0.05a

0.989 ± 0.06a

1.057 ± 0.05a

0.34 ± 0.05b

42

b

b

a

0.801 ± 0.11

* Values are not significant (P > 0.05).
**Values with same superscripts in a row have no significant
difference (P > 0.05).
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Control

0.795 ± 0.09

1.108 ± 0.05

0.363 ± 0.07c

R. RAJAGOPAL, G. K. NAIR, M. MANGATTUMURUPPEL, J. LEO, S. R. MAPRANATH

Table 3. Homogeneous challenge with 200 and 100 LD50 doses of virulent DP1 in ducklings.
Type of vaccine
CV

CEV

BV

Control

Dose of inoculum

Days postinoculation

Survived/total tested

% protection

200 LD50

28

6/10

60

100 LD50

42

8/10

80

200 LD50

28

6/10

60

100 LD50

42

8/10

80

200 LD50

28

7/10

70

100 LD50

42

9/10

90

200 LD50

28

2/10

20

100 LD50

42

1/10

10

Discussion
The P. multocida A: 1 strain used in this study was
found to be an in vitro biofilm former. However,
it was very difficult to obtain enough biomass for
vaccine preparation. As a result, the biofilm mode of
growth was first induced, and then it was subcultured
onto nutrient agar. Bacteria were found to retain the
biofilm mode of growth for a few subcultures in agar
media, which was consistent with the findings of
Kaplan and Mulks (11) in the case of Actinobacillus
pleuropneumoniae field isolates. This modification is
useful, as it makes the process of vaccine preparation
more amenable to commercial production of the
vaccine.
It is interesting to note that the pattern of antibody
response elicited by BV simulates subunit vaccines
employing outer membrane proteins (12) and live
vaccines (13). The antibody response was unusually
rapid; it peaked during the 14th day PV and also
maintained a reasonable titre during the entire period
of study (45 days). This may be attributable to the
uncanny semblance of biofilms to conditions in vivo
and the better presentation of antigens. Organisms
grown in vivo express the cross protective factors that
make them capable of providing a broader immunity
in terms of heterologous protection (14). Biofilms
exhibit many novel proteins that are conserved,
and out of these many could be immunodominant
(15). Most of the bacterial diseases involve biofilm
formation inside the host body, and the presentation
and familiarisation of such epitopes to the host body
may be a reason for the better immune response of

biofilm vaccine. To exploit the expression of novel
heat shock proteins and simulate the natural body
condition of the birds, biofilm cultures in the present
study were subjected to nutrient limitation and a
higher temperature (42 °C) (16).
Sometimes even if antibodies against a particular
organism are present in the host body, they may
not be capable of providing the host with sufficient
protection against biofilm mediated infections (17).
This highlights the importance of familiarising the
host body with antigens specific to biofilm, which
may not be present in planktonic bacteria. Shivaraj
(18) reported an exceptional 83.33% protection
for a biofilm based oral vaccine for E. coli; the
conventional vaccine could induce only 33.33%
protection. Although the BV in the present study did
not produce such an enormous improvement over
the conventional vaccine, it did ensure 10% more
protection than both CV and CEV.
CV and CEV revealed similar titres and
protection rates, in accordance with the findings of
Ramanatha (19) and Akand et al. (20). With capsule
enhancement no added advantage was obtained,
which was consistent with the findings of Somarajana
et al. (21).
Conclusion
In conclusion, the biofilm vaccine was the best
among the 3 vaccines examined in the present
study, as it provided stronger and lasting immunity.
The protection rates of capsule enhanced bacterin
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and the conventional bacterin were the same. The
present study is only a preliminary investigation and
provided some information on the biofilm formation
of P. multocida and the utility of its biofilm as vaccine.
Outer membrane subunit vaccines were found to be
effective by various researchers, and they would be
more effective if the outer membrane proteins of
biofilm cells were used.
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